Alzheimer's tau markers differed in how they tracked amyloid removal
In a secondary analysis of an inherited-Alzheimer's trial, some spinal-fluid tau markers changed with plaque reduction, while others tracked tau pathology without the same association.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Some tau markers in cerebrospinal fluid fell alongside amyloid-plaque reduction with gantenerumab, while later-changing markers were not associated with plaque reduction. The analysis suggests that different tau measurements reflect different aspects of Alzheimer's pathology. These are biomarker findings: the abstract does not report whether the changes were accompanied by improvements in memory, everyday function or symptoms.
This was a post-hoc biomarker analysis in people at risk for inherited Alzheimer's disease. The abstract provides no clinical outcome results and does not establish applicability to other Alzheimer's populations.
What the analysis measured
Researchers used mass spectrometry to measure several tau forms in cerebrospinal fluid. They examined how those measurements related to amyloid plaques and tau tangles, asking whether the markers followed the same underlying changes.
Different markers, different signals
The earlier-changing tau forms tracked amyloid reduction, whereas later-changing forms aligned with tangle progression. The reported treatment-linked pattern concerned gantenerumab; the abstract does not provide corresponding detailed results for solanezumab or numerical comparisons with placebo.
The original publication
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology.
McDade EM, Barthélemy NR, Wang G et al.
Alzheimers Dement · 2025
- PubMed ID
- 40985290
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.